Format

Send to

Choose Destination
Metabolomics. 2019 Mar 27;15(4):54. doi: 10.1007/s11306-019-1513-6.

The GC-MS metabolomics signature in patients with fibromyalgia syndrome directs to dysbiosis as an aspect contributing factor of FMS pathophysiology.

Author information

1
Faculty of Natural and Agricultural Sciences, Centre for Human Metabolomics, North-West University (Potchefstroom Campus), Private Bag X6001, Potchefstroom, South Africa.
2
Faculty of Natural and Agricultural Sciences, Centre for Human Metabolomics, North-West University (Potchefstroom Campus), Private Bag X6001, Potchefstroom, South Africa. nmr.nwu@gmail.com.
3
Translational Metabolic Laboratory, Department of Laboratory Medicine, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB, Nijmegen, The Netherlands.
4
Department of Family Medicine, Kalafong Hospital, University of Pretoria, Private Bag X396, Pretoria, South Africa.

Abstract

INTRODUCTION:

Fibromyalgia syndrome (FMS) is a chronic pain syndrome. Previous analyses of untargeted metabolomics data indicated altered metabolic profile in FMS patients.

OBJECTIVES:

We report a semi-targeted explorative metabolomics study on the urinary metabolite profile of FMS patients; exploring the potential of urinary metabolite information to augment existing medical diagnosis.

METHODS:

All cases were females. Patients had a medical history of persistent FMS (n = 18). Control groups were first-generation family members of the patients (n = 11), age-related individuals without indications of FMS (n = 10), and healthy, young (18-22 years) individuals (n = 41). The biofluid investigated was early morning urine samples. Data generation was done through gas chromatography-mass spectrometry (GC-MS) analysis and data processing and analyses were performed using Matlab, R, SPSS and SAS software.

RESULTS:

Quantitative analysis revealed the presence of 196 metabolites. Unsupervised and supervised multivariate analyses distinguished all three control groups and the FMS patients, which could be related to 14 significantly increased metabolites. These metabolites are associated with energy metabolism, digestion and metabolism of carbohydrates and other host and gut metabolites.

CONCLUSIONS:

Overall, urinary metabolite profiles in the FMS patients suggest: (1) energy utilization is a central aspect of this pain disorder, (2) dysbiosis seems to prevail in FMS patients, indicated by disrupted microbiota metabolites, supporting the model that microbiota may alter brain function through the gut-brain axis, with the gut being a gateway to generalized pain, and (3) screening of urine from FMS is an avenue to explore for adding non-invasive clinical information for diagnosis and treatment of FMS.

KEYWORDS:

Biomarkers; Carbohydrate; Dysbiosis; Fibromyalgia syndrome (FMS); Gas chromatography–mass spectrometry (GC–MS); Pain

PMID:
30919098
DOI:
10.1007/s11306-019-1513-6

Supplemental Content

Loading ...
Support Center